/ Active, not recruitingPhase 1 A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
100 Clinical Results associated with MICA x MICB x Top I
100 Translational Medicine associated with MICA x MICB x Top I
0 Patents (Medical) associated with MICA x MICB x Top I